https://nsc10483agonist.com/th....e-impact-of-epi-base
Epalrestat along with sorafenib inhibited HepG2 cellular proliferation in vitro, arrested the cell cycle at G0/G1, and promoted apoptosis and autophagy. Treatment with a particular mTOR activator MHY-1485 increased mTOR phosphorylation, while suppressing apoptosis and autophagy. In line with in vitro results, data through the HCC-xenograft nude mouse model also suggested that combined treatment inhibited the mTOR pathway and presented apoptosis and autophagy. In closing, epalrestat heigh
Like
Comment
Share
